Select Page

Over the past year, a variety of promising immunotherapy (I/O) treatments has risen to the forefront of biotech, creating an exciting set of implications surrounding this prevailing breakthrough in modern medicine.

I previously explored a few of 2018’s biggest names I/O. Here now is a quick look at current developments, failures and future projections surrounding two more contemporary products.


Five Prime’s Cabiralizumab

Cabiralizumab, an antibody, works to inhibit colony stimulating factor-1 receptor (or CSF1R), which, in increased levels, has been found in microglia in Alzheimer’s disease following brain injuries. CSF1R is also overexpressed in several types of cancer. Cabiralizumab “targets tumor-associated macrophages (TAMs), which are elevated in many tumors and thought to be involved in suppressing the immune response against tumors.”

  • Current Clinical Trial Phase: In January 2018, BMS entered a phase 2 clinical trial of cabiralizumab combined with Opdivo, assessing the treatments with and without chemotherapy for patients with advanced pancreatic cancer — mainly those who saw the disease progress after first-line chemotherapy. At the same time, Five Prime has also initiated a phase 2 trial of Cabiralizumab monotherapy for patients with PVNS, a “rare, locally aggressive tumour of the synovium.”
  • Results (to date): Current clinical trials remain underway at this time.


Array Biopharma’s ARRY-382

With several clinical trials either completed or currently in process, Array Biopharma’s ARRY-382 is already well on its way to becoming a household name in modern I/O. Like Cabiralizumab, the treatment was mainly designed as an inhibitor of CSF1R.

  • Projected Sales: Given numerous ongoing trials of its various products, hard-and-fast Arrya’s projected 2018 sales figures are currently undetermined. However, its evolving pipeline of products, including ARRY-382, suggests a strong annual performance.


Array Biopharma’s stock figures during 2018 thus far

  • Current Clinical Trial Phase: ARRY-382 is currently being put through an open-label multicenter phase 1b/2 study to determine its “maximum tolerated dose and/or recommended phase 2 dose.” This study is estimated to complete by April 2020.
  • Results (to date): Following a phase 1 study assessing ARRY-382’s safety, pharmacokinetics, and pharmacodynamics, a “dose and schedule that demonstrates target engagement based on multiple pharmacodynamic biomarkers” was pinpointed as a subject for future study.